Amberstone Biosciences

Amberstone Biosciences

  • Founded: 2018
  • Location: Laguna Hills, CA
  • Employee range: 11 - 50
  • Clinical stage: Clin0
  • Therapy area: Oncology
  • Drug types: ONC
  • Lead product: ABS-101
  • Product link:
  • Funding: $12M A Jan 2022

job board

Short description:

Solid Tumor Therapies

Drug notes:

ABS-102 RD oncology; ABS-110 RD oncology; ABS-280 RD oncology

Long description:

Amberstone Biosciences aims to create safe and effective immunotherapies. Their T-MATE: Tumor Microenvironment Activated Therapeutics pipeline is made of therapeutic antibodies that target tumors with less off-target damage. Amberstone utilizes their discovery platform, AmberFlow, a high-throughput method to identify novel therapeutic targets via proprietary single-cell microfluidics. AmberFlow’s technology can evaluate candidates quickly, producing high-content information without limitations of molecular format, cell source, or target. Amberstone’s pipeline strategy can target various tumor types and autoimmune diseases.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy